Why is Alembic Pharma falling/rising?

As of 23-Jul, Alembic Pharmaceuticals Ltd. is currently priced at 1,015.85, reflecting a slight increase of 0.2 (0.02%). The stock has recently experienced a trend reversal, gaining after three consecutive days of decline. However, it has underperformed its sector by 0.49% today, and its delivery volume has decreased significantly by 37.55% compared to the five-day average, indicating falling investor participation. Over the past week, the stock has declined by 0.78%, while it has shown a positive return of 8.32% over the past month. Despite a year-to-date decline of 4.09%, the company's strong ability to service debt, as evidenced by a low Debt to EBITDA ratio of 0.67 times, and an attractive valuation with a return on capital employed (ROCE) of 11.5, suggest some underlying strength.
In the broader market context, the Sensex has increased by 0.11% over the past week, contrasting with Alembic's decline. While the stock has underperformed the benchmark in the short term, it has shown resilience over a three-year period with a return of 43.43%, although it lags behind the Sensex's 47.54% return in the same timeframe. High institutional holdings at 20.42% indicate that knowledgeable investors are backing the stock, which may provide some stability despite its recent struggles. Overall, while the stock has faced challenges, its fundamentals suggest potential for recovery, albeit within a market that has been more favorable to the broader index.